Metformin: update on mechanisms of action and repurposing potential

M Foretz, B Guigas, B Viollet - Nature Reviews Endocrinology, 2023‏ - nature.com
Currently, metformin is the first-line medication to treat type 2 diabetes mellitus (T2DM) in
most guidelines and is used daily by> 200 million patients. Surprisingly, the mechanisms …

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

JM Llovet, CE Willoughby, AG Singal… - Nature reviews …, 2023‏ - nature.com
Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

Exploiting innate immunity for cancer immunotherapy

M Yi, T Li, M Niu, Q Mei, B Zhao, Q Chu, Z Dai, K Wu - Molecular cancer, 2023‏ - Springer
Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

A researcher's guide to preclinical mouse NASH models

S Gallage, JEB Avila, P Ramadori, E Focaccia… - Nature …, 2022‏ - nature.com
Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …

[HTML][HTML] The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease

K Sawada, H Chung, S Softic, ME Moreno-Fernandez… - Cell metabolism, 2023‏ - cell.com
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an unabated risk factor
for end-stage liver diseases with no available therapies. Dysregulated immune responses …

Metabolic reprogramming in the tumor microenvironment of liver cancer

J Lin, D Rao, M Zhang, Q Gao - Journal of hematology & oncology, 2024‏ - Springer
The liver is essential for metabolic homeostasis. The onset of liver cancer is often
accompanied by dysregulated liver function, leading to metabolic rearrangements …

GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis

T Chen, Y Meng, Z Zhou, H Li, L Wan, A Kang… - Cell Death & …, 2023‏ - nature.com
Nonalcoholic fatty liver disease (NAFLD) is characterised by hepatic steatosis, inflammation,
and insulin resistance. The role of long noncoding RNA (lncRNA)-regulated pyroptosis in …

Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making

R Dhanasekaran, H Suzuki, L Lemaitre, N Kubota… - Hepatology, 2025‏ - journals.lww.com
Liver cancer, primarily HCC, exhibits highly heterogeneous histological and molecular
aberrations across tumors and within individual tumor nodules. Such intertumor and …

Phenotypes of metabolic dysfunction–associated steatotic liver disease–associated hepatocellular carcinoma

J Rivera-Esteban, S Muñoz-Martínez, M Higuera… - Clinical …, 2024‏ - Elsevier
Hepatocellular carcinoma (HCC) typically develops as a consequence of liver cirrhosis, but
HCC epidemiology has evolved drastically in recent years. Metabolic dysfunction …

[HTML][HTML] Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect

L Zhu, K Yang, Z Ren, D Yin, Y Zhou - Translational oncology, 2024‏ - Elsevier
Metformin, as the preferred antihyperglycemic drug for type 2 diabetes, has been found to
have a significant effect in inhibiting tumor growth in recent years. However, metformin alone …